Format

Send to

Choose Destination
J Hepatol. 2016 Oct;65(1 Suppl):S120-S129. doi: 10.1016/j.jhep.2016.08.001.

Management of the patient with SVR.

Author information

1
University of California San Francisco, USA. Electronic address: norah.terrault@ucsf.edu.
2
University of California San Diego and Southern California GI and Liver Centers, USA. Electronic address: thassanein@livercenters.com.

Abstract

In the current era of therapy with direct-acting antiviral (DAAs) drugs, achievement of a sustained virological response (SVR) is achievable in ⩾90% of hepatitis C-infected patients. SVR benefits are well-recognized with reductions in rates of liver complications, hepatocellular carcinoma and mortality. Additional benefits include reduced morbidity related to extrahepatic and systemic manifestations of hepatitis C such as renal, dermatologic, and metabolic complications. However, not all patients will derive all of these benefits and monitoring for progression is necessary, especially in those with more advanced fibrosis. To maximize the health benefits of SVR, counseling patients on best means to maintain good liver health and prevent reinfection are also important.

KEYWORDS:

Fibrosis regression; Liver-related mortality; Prevention; Sustained virological response

PMID:
27641982
DOI:
10.1016/j.jhep.2016.08.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center